Skip to main content

Prevention of MSSA Bacteremia and treatment with Nafcillin and Ceftriaxone




Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia is associated with high morbidity and mortality. Usually, antistaphylococcal penicillins (ASPs) have been considered the agents of choice for the treatment of MSSA bacteremia. 

Optimal medication therapy for MSSA infections is unclear. Current standard of care consists of nafcillin, oxacillin and cefazolin. Ceftriaxone has advantage as a once-daily outpatient regimen. (1)

Current evidence suggests there is no difference in efficacy between ceftriaxone and ASPs for MSSA infection, with a lower risk of toxicity with ceftriaxone. Ceftriaxone is a good option for definitive therapy of MSSA infection. (1)

Real time patient medications:

Diagnosis: Back pain, sepsis due to MSSA bacteremia and Lumbar spine abscess.

Nafcillin 10 G Vial (Nafcil) 12gram/1.2vial(s) in Sodium Chloride 0.9% 500 mL, Infuse 12 gm over 24 Hours intravenously Every 24 Hours, Rate: 20.8 mL/Hour GIVE CEFTRIAXONE IV FIRST THEN START NAFCILLIN INFUSION CONTINUE FOR EIGHT WEEKS. DC ON SEPTEMBER 9, 2022 Indication: MSSA: BACTEREMIA

CefTRIAXone 2 G Vial (Rocephin) 2gram/1vial(s) in Sodium Chloride 0.9% 50mL, Infuse 2 gm over 30 Minutes intravenously Every 24 Hours, Rate: 100 mL/Hour CONTINUE FOR SIX WEEKS. DC ON AUGUST 29, 2022 *DOCUMENT FLUSH BEFORE AND AFTER ACCESS* Indication: MSSA: BACTEREMIA

oxyCODONE IR (OxyIR) Give 5 mg (1 tablet(s)) by mouth Every Four Hours PRN Look Alike Sound Alike Medication Indication: moderate pain (4-6)
Lidocaine 4% Patch (Salonpas) Apply 1 patch(es) topically Daily

Mirabegron ER (Myrbetriq) Give 50 mg (1 tablet(s)) by mouth Daily
Heparin 5000 Unit/mL Vial (heparin SODIUM) Inject 5000 unit (1 mL) subcutaneously Every Eight Hours Look-Alike/Sound-Alike *High Alert*

Preventing strategies for MSSA infection: 

Wash hands; wear gloves; keep wounds covered; keep personal items like towels, sheets and razors separate

References:

1. Yetmar ZA, Razi S, Nayfeh T, Gerberi DJ, Mahmood M, Abu Saleh OM. Ceftriaxone versus antistaphylococcal antibiotics for definitive treatment of methicillin-susceptible Staphylococcus aureus infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2022 Jan;59(1):106486. doi: 10.1016/j.ijantimicag.2021.106486. Epub 2021 Nov 26


Comments

Post a Comment

Popular posts from this blog

Sodium chloride Tablets USP

A 91- year old patient. Admitted to the hospital from the ED. Patient was seen for altered mental status. Labs, CT of brain head, CXR XR of left Tib/Fib were performed. Presumed meningioma in the left middle cranial fossa was noted. Sodium was critically low at 114. Nephrologist was consulted and hyponatremia is of unknown etiology. Patient also has uncontroled hypertension. Comorbidities: Coronary artery disease, Diabetes, Dementia, hypothyroidism, hyperlipedemia, neuropathy. Patient will need physicain oversight for hyponatremia, normal saline routinely, and medication management for hypertension. Rx: Sodium Chloride USP 1.0 gram Use  1. Hyponatremia 2. Preparation of normal isotonic solution of sodium chloride 3. As an electrolyte replenisher for the prevention of heat cramps, due to excessive  perspiration 4. any alternate use as directed by a physician Each tablet contains: sodium 394mg Hyponatremia  is a common electrolyte disorder encountered i...
7 comments
Read more

Mounjaro, Is it a game changer for weight loss and diabetes?

  MOUNJARO™ ( Tirzepatide) was approved for medical use in the United States in May 2022 WEIGHT LOSS: (Not approved by FDA for weight loss) Eli Lilly and Company is  finalizing an application to the U.S. Food and Drug Administration for fast-track approval to sell tirzepatide for chronic weight management. MOUNJARO™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in adults for type 2 diabetes mellitus management. CONTRAINDICATIONS Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2  Known serious all to tirzepatide or any of the excipients in MOUNJARO                                                                    ...
Post a Comment
Read more

Heart healthy

*Clinical atherosclerotic cardiovascular disease (ASCVD) includes acute coronary syndrome (ACS), those with history of myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin. Should I initiate statins or not? The 2014 National Lipid Association (NLA) recommendations provides a more comprehensive, patient-centered approach to identifying ASCVD risk.   In 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) issued guidelines to use the intensity of statin therapy as the treatment goal instead of LDL-C or non–HDL-C targets, as in previous guidelines, to reduce atherosclerotic cardiovascular disease (ASCVD) risk (  Andrus & Lacaille, 2014  )  The guideline classifies statin therapy as  high-intensity (lowers LD...
7 comments
Read more